Title : Novel Lawsone-Quinoxaline Hybrids as New Dual Binding Site Acetylcholinesterase Inhibitors - Suwanhom_2023_ACS.Omega_8_32498 |
Author(s) : Suwanhom P , Nualnoi T , Khongkow P , Tipmanee V , Lomlim L |
Ref : ACS Omega , 8 :32498 , 2023 |
Abstract :
A new family of lawsone-quinoxaline hybrids was designed, synthesized, and evaluated as dual binding site cholinesterase inhibitors (ChEIs). In vitro tests revealed that compound 6d was the most potent AChEI (IC(50) = 20 nM) and BChEI (IC(50) = 220 nM). The compound 6d did not show cytotoxicity against the SH-SY5Y neuronal cells (GI(50) > 100 microM). In silico and enzyme kinetic experiments demonstrated that compound 6d bound to both the catalytic anionic site and the peripheral anionic site of HuAChE. The lawsone-quinoxaline hybrids exhibited potential for further development of potent acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. |
PubMedSearch : Suwanhom_2023_ACS.Omega_8_32498 |
PubMedID: 37720764 |
Suwanhom P, Nualnoi T, Khongkow P, Tipmanee V, Lomlim L (2023)
Novel Lawsone-Quinoxaline Hybrids as New Dual Binding Site Acetylcholinesterase Inhibitors
ACS Omega
8 :32498
Suwanhom P, Nualnoi T, Khongkow P, Tipmanee V, Lomlim L (2023)
ACS Omega
8 :32498